Analysis of the Treatment Costs of Malignant Tumor Diseases in China’s Hunan Province Based on“System of Health Account 2011”

preprint OA: closed CC-BY-4.0
📄 Open PDF View at publisher

Abstract

Objective: To calculate and analyze the treatment costs of malignant tumors in Hunan Province in 2019, and to provide data support for the formulation and implementation of policies by the health department. Methods: : Refer to the "2019 Hunan Province Health Finance Annual Report" and "2019 Hunan Province Health Statistics Summary", based on the “System of Health Account 2011”, calculate and analyze the disease types, beneficiaries, institutional distribution and financing status of malignant tumors diseases. Results: : In 2019, the total cost of malignant tumor treatment in Hunan Province was 440,596,800 yuan. The top five were malignant tumors of digestive organs (40.10%), malignant tumors of respiratory and intrathoracic organs (17.62%), and malignant tumors of breast (12.24%), female genital organ malignant tumors (9.88%) and lip, oral cavity and pharynx malignant tumors (6.87%). The 35 to 79-year-old age group has higher treatment costs. The costs are concentrated in general hospitals. Funding sources mainly come from government financing and family health expenditure. The main influencing factors of malignant tumor hospitalization expenses are gender, length of stay, age, drug proportion, institution level and medical institution type. Conclusions: : The disease burden of malignant tumors is relatively serious; primary medical and health institutions lack health resources; and household health expenditure accounts for a relatively high proportion. Therefore, hierarchical diagnosis and treatment should be promoted reasonably, focused on key diseases and populations, and medical security policies should be improved to ensure that patients with malignant tumors and their families’ economic burden of disease can be reduced.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-05-19T01:45:01.086888+00:00
unpaywall
last seen: 2026-08-12T06:43:03.944938+00:00
License: CC-BY-4.0